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ABSTRACT non-enzymatic protein glycation is a source of metabolic stress that contributes to cytotoxicity and tissue damage.  Hyperglycemia has been linked 
to elevation of advanced glycation endproducts, which mediate much of the vascular pathology leading to diabetic complications. enhanced glycation of im-
munoglobulins and their accelerated vascular clearance is proposed as a natural mechanism to intercept alternative advanced glycation endproducts, thereby 
mitigating microvascular disease. We reported that antibodies against the glycoprotein KLH have elevated reactivity for glycopeptides from diabetic serum. these 
reactions are mediated by covalent binding between antibody light chains and carbonyl groups of glycated peptides. Diabetic animals that were immunized to 
induce reactive antibodies had attenuated diabetic nephropathy, which correlated with reduced levels of circulating and kidney-bound glycation products. Mo-
lecular analysis of antibody glycation revealed the preferential modification of light chains bearing germline-encoded lambda V regions. We previously noted that 
antibody fragments carrying V regions in the germline configuration are selected from a human Fv library by covalent binding to a reactive organophosphorus 
ester. these Fv fragments were specifically modified at light chain V region residues, which map to the combining site at the interface between light and heavy 
chains. these findings suggest that covalent binding is an innate property of antibodies, which may be encoded in the genome for specific physiological purposes. 
this hypothesis is discussed in context with current knowledge of the natural antibodies that recognize altered self molecules and the catalytic autoantibodies 
found in autoimmune disease.
Keywords:  natural autoantibodies, covalent binding, reactive antibody, advanced glycation, carbonyl group, diabetic complications, hydrolytic abzymes
Abbreviations: nAbs, natural antibodies; KLH, Keyhole limpet hemocyanin; VL, light chain variable region; VH, heavy chain variable region; cDr, complemen-
tarity determining region; LDL, low-density lipoprotein; AGes, advanced glycation endproducts; rAGe, receptor of AGe; OP, organophosphorus ester; scFv, 
single-chain variable fragment; Fr, framework region; Pc, phosphorylcholine; PAMPs, pathogen-associated molecular patterns; tLr, toll-like receptor.
INTRODuCTION
the generation of an enormous diversity of antibodies in re-
sponse to the multitude of possible antigens is a signature of 
instructive or adaptive immunity. the structural basis for 
adaptive immunity is expressed in the variability of the an-
tigen binding sites displayed on antibodies and B cell recep-
tors. thus, antibodies are conventionally associated with the 
genetic recombination and accumulated mutations in their 
variable (V) regions that incrementally improve the comple-
mentarity between the antibody combining site and groups 
on the antigen. In contrast to affinity that matures gradu-
ally over time through multiple weak interactions, binding 
through strong forces such as a covalent bond could enable a 
more rapid and efficient way to capture certain antigens. Is 
there any case where antibodies use this form of binding and 
what purpose could such a binding mechanism serve? 
Antibodies that bind ligands covalently have been sought 
in approaches to generate enzyme-like catalytic antibodies (1). 
covalent binding is used by enzymes to stabilize reactive in-
termediates in catalysis of many types of reactions. reactive 
immunization was conceived as a strategy to elicit antibodies 
that bind their ligands through a covalent complex (2). Such 
antibody complexes might mimic enzyme intermediates to cat-
alyze the transformation of the bound substrate. the premise 
assumes that this form of binding could be evoked through the 
conventional affinity maturation process for antibody induc-
tion. Implicitly, such antibodies would have experimentally 
conferred, and therefore artificial, activity.  In the prototypi-
cal example, immunization against synthetic antigens contain-
ing a reactive dicarbonyl group provided antibodies that bind 
through Schiff base - enamine adducts. the covalently reac-
tive clones were shown to possess remarkable aldolase activity 
(2). As predicted, the covalent binding function arises from the 
somatically mutated V region genes, positioning one or more 
nucleophilic lysine residues in the combining site (3).
COVALENT BINDINg ANTIBODIES IN 
gLYCATION AND PAThOLOgY
In an alternative framework one could postulate that cova-
lent binding antibodies might also occur naturally if this 
activity were advantageous to the host. We proposed that 
binding through a single strong interaction to an antibody 
would be an appropriate mechanism for the sequestration 
and clearance of chemically damaged proteins and cells. Such 
a function is increasingly recognized in studies of naturally 
occurring antibodies that have inherent affinity for altered 
structures on self (4). For example, certain IgM antibodies 
that compete with macrophage receptors for binding of oxi-
dized LDL particles rely on the recognition of distinct chemi-
cal moieties such as the phosphorylcholine headgroup on oxi-
dized phospholipids. these natural autoantibodies (nAbs) are 
encoded in the germline and typically lack somatic mutations 
(5). Armed with this “innate-like” reactivity, nAbs are be-
lieved to constitute a disposal system for continuous surveil-reVIeWS
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lance and elimination of altered self, or “neoantigens” shed 
from apoptotic cells and damaged tissues (6). the same nAbs 
also bind to phosphorylcholine groups on bacterial cell wall 
polysaccharides, thus providing a first line of defense against 
infections (7). this dual purpose could explain the conserva-
tion of this function in the germline repertoire. the molecular 
basis for the interaction of V regions of nAbs with oxidized 
phospholipids remains under investigation.
Another kind of cytotoxic metabolic waste is generated 
through glycation or glycoxidation as sugars and carbohy-
drates are constantly bathing proteins and cells and modify-
ing them through nonspecific reactions of their exposed car-
bonyl groups. Glycation is a slow and continuous process that 
occurs in normal aging. However, it is significantly elevated 
in diabetes due to recurring hyperglycemia or poor glycemic 
control. the role of this pathway in leading to vascular com-
plication of diabetes is now firmly established (8-10). A be-
wildering array of advanced glycation endproducts (AGes) 
constitutes a class of altered self, which has only been super-
ficially characterized.  AGes initiate pathologies of vascular 
tissues by two major mechanisms: alteration of the extracel-
lular matrix through protein crosslinks, and the modulation 
of cellular functions by interacting with specific receptors. 
Diverse routes of cytotoxicity are suggested by the variety of 
receptors implicated in AGe uptake, including the receptor 
of AGe (rAGe), macrophage scavenger receptor, galectin-3 
and megalin (11-15).  the resulting cellular responses, includ-
ing plaque formation and tissue restructuring, contribute to 
the progression of cardiovascular, renal, and microvascular 
diseases (Figure 1). A number of approaches to therapy of 
AGe-related pathogenesis are under investigation, including 
pharmacological inhibition of AGe formation (16) and biop-
harmaceutical blockade of AGe receptors (17).  In principle, 
a natural homeostatic mechanism to deplete cytotoxic AGes 
from circulation could mitigate pathology from ongoing or 
excessive glycation. Such a mechanism would likely include 
regulation to boost protection in a stress response. Is there 
a molecular basis for antibodies to fulfill such a housekeep-
ing function? While AGes can be highly heterogeneous, the 
chemical intermediates leading to their formation often bear 
carbonyl groups derived from the reducing sugars as a dis-
tinct chemical signature (18). Initially, carbonyls are intro-
duced through the Amadori reaction and may be retained in 
various protein adducts generated in the subsequent Mail-
lard reaction. Further degradation of these adducts produces 
low molecular weight aldehydes, dialdehydes, and glycated 
peptides, which can react again to modify other proteins 
(Figure 2). thus, the concept of “carbonyl stress” has come to 
denote the chronic pathologies resulting from glycation and 
oxidation.  An obvious mechanism to mitigate cytotoxic AGe 
formation is to reduce the carbonyl load. A reducing envi-
ronment within cells allows one level of protection. However, 
extracellular scavengers might also be expected to protect 
targets in circulation, on cell surfaces, and in the interstitial 
space. the efficacy of certain carbonyl-reactive pharmaceu-
tical agents (19) and of monoclonal anti-Amadori albumin an-
tibodies (20, 21) in therapy of diabetic complications provides 
a further rationale to implicate natural carbonyl scavenging. 
covalent binding by antibodies would have distinct advan-
tages in this capacity, which conventional antibody binding 
could not match.  In the hypothetical immune process, a com-
mon antibody would recognize diverse modified antigens by 
strong covalent binding to the carbonyl residue, rather than 
requiring many antibodies to bind a multitude of convention-
al epitopes on all the possible glycation products.
A favorable chemical reaction of antibodies with glycation 
products is suggested by the enhanced glycation of normal 
immunoglobulins (22-24). Glycated peptides from diabetic 
animals were shown to react in vitro with normal IgG to mod-
ify their L chains (25). Furthermore, glycated L chain is one 
of three major serum proteins isolated from diabetic subjects 
(26). Most proteins can undergo glycation to a varying de-
gree, with some proteins more reactive than others. Hence, 
the modification of immunoglobulin is not surprising in itself, 
but the selectivity for L chain suggested that highly reactive 
sites must be available on these polypeptides. the chemical 
reactivity of L chains could be attributed to their unique se-
quences found in either the constant or variable domain. the 
preferential glycation of Fab and Fv (22, 24) and impaired 
antigen binding of glycated antibodies (23) support the idea 
that reactive residues are located in the variable sequences. 
Accordingly, reactivity might also be modulated by somatic 
diversification of V region sequences of the L chains.
INDuCTION OF COVALENT BINDINg ANTIBODIES
In order to test this hypothesis we sought to demonstrate 
that covalent binding antibodies could be elevated in an im-
mune response and that these could attenuate a glycation 
stress by reducing the carbonyl load. reactive immunization 
suggested a feasible approach.  Previously, we showed that 
antibodies induced to a pyruvate-containing hapten-KLH 
conjugate could bind to antigen by recognizing only the car-
bonyl group in the hapten (27). However, to our surprise the 
anti-KLH antibodies accounted in large part for this reac-
tivity. Antibodies to KLH bound to the reactive pyruvate in 
the same way as established by differential binding to the 
pyruvate/glycolate hapten pair (Figure 3). covalent Schiff 
base formation between antibody and the pyruvate carbonyl 
was the most plausible explanation for this focused binding. 
to test whether these antibodies could also neutralize car-
bonyl groups on glycation products, we compared anti-KLH 
antibody and normal IgG in the reaction with glycated pep-
tides from sera of diabetic rats.  In fact, this assay showed 
that L chains of anti-KLH antibody were more reactive than 
L chains of normal IgG (28). the chemically reduced glycat-
ed peptides failed to form covalent adducts, indicating that 
carbonyl groups were necessary for the reaction (Figure 4). 
Proteomic analysis of the modified L chains by tandem mass 
spectrometry showed V region peptides derived from only 
two lambda L chains, even though kappa L chains comprise 
more than 90% of rat IgG. remarkably, these lambda L chain 
peptides revealed sequences identical to the germline-en-
coded VL (28). However, these results also suggested that L 
chain reactivity was enhanced by immunization. Although 
mass analysis detected only peptides of unmutated germline 
VL, modified peptides with mutated residues might not have 
been identified by proteomic analysis. Alternatively, L chains 
with innate reactivity might be recruited in combination with 
somatically diversified VH domains, which provide specificity 
for KLH and cross-reactivity for glycated peptides.68 | ActA nAturAe |  № 2 2009
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REACTIVE ANTIBODIES AMELIORATE 
gLYCATION-ASSOCIATED PAThOLOgY
the streptozotocin-induced diabetic rat, serving as a suitable 
model for diabetic nephropathy, was used to demonstrate 
the potential of the reactive immune response to mitigate 
AGe formation in vivo. compared to diabetic animals immu-
nized with adjuvant alone, KLH-immunized diabetic rats had 
significantly diminished AGe levels, which correlated with 
attenuated nephropathy (28). Improved renal function, as 
determined by glomerular morphology and proteinuria lev-
els, was accompanied by reduced AGe staining in the renal 
extracellular matrix. We hypothesized that the therapeutic 
benefit derived from improved capture of glycation prod-
ucts in circulation by the reactive antibodies. this mecha-
nism presumes that AGes formed from antibody molecules 
are less cytotoxic than the alternative protein AGes. Forma-
tion of glycated IgG in diabetic subjects and, in particular, 
the identification of glycated L chain in the diabetic serum 
(26) indicated that these molecules might play a role in AGe 
pathogenesis. Although modified L chains accumulated in the 
reaction with glycated peptides in vitro, these products were 
not significantly elevated in the serum of diabetic animals. 
Glycated IgG is cleared from circulation and taken up by kid-
ney more efficiently than unmodified IgG (29). Furthermore, 
the filtration properties of low mass glycated proteins favor 
their selective excretion (30). thus, native and modified L 
chains are found in the urine of both healthy and diabetic 
subjects (31, 32). taken together, these observations are con-
sistent with the hypothesis of enhanced clearance of selec-
tively glycated antibodies. 
these studies provide evidence that a natural covalent 
reactivity of antibodies is augmented by adaptive immuni-
ty.  However, the predominance of unmutated V region se-
quences in the reaction products suggested that reactivity is 
inherent to the germline encoded VL (28). How could reactiv-
ity be enhanced by affinity maturation, yet conserved in an 
unmutated germline configuration? Glycosylated residues of 
KLH are believed to account for the cross-reactivity of anti-
KLH antibodies for carbohydrate epitopes of microbial anti-
gens (33). Similarly, anti-KLH antibodies may also cross-react 
against glycosylated epitopes of tumor antigens, as suggested 
by the therapeutic benefits of KLH in bladder carcinoma (34).   
thus, a carbohydrate-specific response could account for the 
specificity of KLH antibodies for glycated peptides. this spe-
cificity could be imprinted in the H chain, which when paired 
with a nonspecific, reactive L chain would enhance reactivity 
of the latter against the bound substrate. the structures of 
reactive Ig V regions and the adaptive mechanisms guiding 
their reactivity remain subjects for further investigation.
COVALENT BINDINg ANTIBODIES FROM REACTIVE 
SELECTION AND REACTIVE IMMuNIzATION
In an alternative approach, we used synthetic reactive sub-
strates as antigens to probe for antibodies capable of covalent 
binding. this idea followed the original concept that anti-
bodies selected for nucleophilic reactivity could also express 
enzymatic activity through covalent catalysis. Irreversible 
covalent binding to a small organophosphorus (OP) ester was 
used to chemically select single-chain VH-VL fragments 
(scFv) from a phage display library (35).  All of the selected 
chemically reactive scFv molecules were modified on the 
VL polypeptide and could be described by two canonical se-
quences. the more reactive clone A.17 used the DPL-5 germ-
line VL product, which was phosphonylated at tyr37 within 
the framework region Fr-L2. By contrast, six other reactive 
clones used the DPL-3 germline VL, which reacted at tyr32 
in cDr-L1. these nucleophilic tyr residues are conserved in 
the VL germline and three-dimensional models of the scFv 
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Fig. 1. Advanced Glycation Endproducts in Pathology.  Protein glycation 
due to hyperglycemia or normal aging are further modified in the body 
to advanced glycation endproducts. These AGE may be further broken 
down to glycated peptides and low molecular weight AGEs. Both high 
and low molecular weight AGEs could be taken up by vascular tissues by 
cellular receptors and by cross-linking of the extracellular matrix. These 
modifications account for cytotoxicity and tissue necrosis and ultimately 
lead to vascular pathologies as is seen in diabetic complications
Fig. 2. Reactive carbonyls and aldehydes are intermediates in the forma-
tion of cytotoxic AGEs.  Early glycation products are primarily the result 
of Amadori reaction of proteins with reducing sugars.  Further non-
enzymatic fragmentation of these products generate additional reactive 
aldehydes, which participate in the further protein modifications and 
cross-linkages know as the Maillard reaction to produce AGEsreVIeWS
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suggest that either residue can be oriented toward the com-
bining site. However, the models also indicate that the tyr37 
is buried at the interface between VL and VH domains in 
A.17, where it could be sterically inaccessible to ligand contact 
without large conformational motions (Figure 5).  Since the 
library was constructed by shuffling of germline VL and VH 
gene segments, we did not expect natural pairs in the scFv 
(36). nevertheless, the VH chains of reactive clones were rep-
resented primarily by highly homologous sequences belong-
ing to the VH4 family. these results strongly suggested that 
the VH chain plays an important part in enhancing the chem-
ical reaction at residues on the VL region. the scFv could also 
bind other structurally unrelated OP compounds indicating 
a lack of fine specificity for ligand structure (35). the A.17 
scFv was also shown to have modest hydrolytic activity for 
peptide amides and simple carboxylic ester substrates. these 
Ig V regions could thus serve as primitive covalent catalysts. 
Most intriguing is the notion that the reactivity emerges from 
certain germline-encoded VL-VH pairs. Additional studies of 
these monoclonal Fv fragments will be of interest for under-
standing the origins and biochemical functions of chemically 
reactive Ig molecules. 
chemical selections in vitro might represent the first step 
in adaptive immunity for acquisition of reactivity. However, 
the contribution of irreversible covalent binding to clonal se-
lection in vivo remains speculative. using a reactive OP ester-
protein conjugate as immunogen, we examined the potential 
for the immune response to elicit reactive antibodies that are 
modified by the antigen. Antisera against the OP conjugate 
included reactive antibodies, which could be detected by their 
covalent modification with biotin-tagged OP reagent (27). 
remarkably, these polyclonal antibodies were also modified 
predominantly on their L chains.  thus, it appeared that the 
reactivity was enhanced by affinity maturation. However, it 
is not clear whether the covalent binding contributed to clonal 
selection or whether it is merely incidental to the affinity ma-
tured antibodies.  considered as an enzyme system, the rate 
of modification (antigen capture) should increase as the non-
covalent binding, expressed by the Kd of the Michaelis-like 
Ab*OP complex, increases. While affinity maturation does 
not require it, an increasing chemical rate (ks) of irreversible 
covalent modification (Ab-X) might provide kinetic selec-
tion for clonal expansion of B cells (Scheme I). ultimately, the 
question is whether covalent capture of antigen is adopted in 
a natural function for immunity or for host survival.
Scheme I
Clonal Selection
CARBONYL ChEMISTRY OF OxIDATION-DERIVED 
EPITOPES FOR NATuRAL ANTIBODIES
IgM nAbs are predominantly produced by a population of 
long-lived, self-replenishing B-cells, including the B-1 and 
B-1a subsets. It is believed that this B cell repertoire is con-
served in evolution for its contribution to host defense (5). the 
germline-encoded nAbs are best known for their capacity 
to bind conserved determinants on pathogens, referred to 
as pathogen-associated molecular patterns (PAMPs). More 
Fig. 3. Covalent-binding ELISA. Antibodies induced against a pyruvate-
KLH conjugate (anti-2 KLH) or against unmodified KLH reacted specifi-
cally by ELISA with the pyruvate (2) coupled to BSA (filled bars). Binding 
to chemically reduced glycolate-BSA (open bars) could be observed 
with anti-2 KLH antibodies but not with anti-KLH antibodies. Normal, 
non-immune IgG bound poorly to either molecule. We hypothesized 
that this binding is mediated by a reaction resulting in covalent binding of 
the pyruvate carbonyl group with anti-KLH antibodies
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Fig. 4. Reaction of anti-KLH antibodies with glycated peptides from 
diabetic serum. (Right panel) The density of the bands for products at 30 
– 34 kDa detected by SDS-PAGE and immunoblot analysis is plotted as a 
fraction of the total L chain density.  Formation of L chains of higher mass 
was observed in the reaction of antibodies from normal and KLH-immu-
nized rats. The rate of the latter was inhibited in the presence of KLH.  
(Left panel) The reaction of L chains with glycopeptides from diabetic rat 
serum at 0 h (lanes 1 and 3) and 24 h (lanes 2 and 4). Glycopeptides that 
were reduced by sodium borohydride failed to react in this time (lanes 1 
and 2), while the untreated glycopeptides showed enhanced formation 
of L chain adducts at 30 – 34 kDa (lanes 3 and 4)70 | ActA nAturAe |  № 2 2009
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recently it was shown that nAbs also bind to altered epitopes 
on apoptotic cell and self proteins (37). these findings support 
the concept of a homeostatic function of nAbs for clearance 
of debris from cell death and protein decay (6, 38). chemi-
cal structures generated by oxidation and glycoxidation of 
membrane phospholipids are thus the natural targets for 
nAb binding, presenting a case where carbonyl chemistry 
intersects with immune recognition. the phosphorylcholine 
(Pc) headgroup of oxidized phospholipids and Pc residues 
on the bacterial cell wall polysaccharides provide a common 
molecular determinant for the immune and homeostatic 
functions of nAbs (7). As a molecular receptor of PAMPs, the 
nAb V region can be regarded as akin to the evolutionarily 
conserved toll-like receptors (tLr) of innate immunity (39). 
this emerging paradigm has far-reaching implications for 
the linkage between innate and adaptive immunity.
Oxidized phospholipids, which accumulate in atheroscle-
rotic lesions, are targets of both innate and adaptive immu-
nity (40). the role of reactive oxygen chemistry in defining 
epitopes for nAbs or for somatically diversified antibody is 
a subject of continuing investigation. Oxidation in the syn-2 
unsaturated fatty acid chain of the phospholipids introduces 
reactive species, including aldehyde functional groups, into 
the lipid moieties. One hypothesis suggests that the carbonyl 
group serves as the reactive anchor for modification of self 
by the phospholipid moieties. Small aldehydes that are by-
products of lipid peroxidation, such as 4-hydroxynonenal and 
4-hydroxyhexenal, are also implicated in protein damage and 
cytotoxicity and may play a role in autoimmune responses 
(41). Moreover, malondialdehyde, glycolaldehyde, and other 
reactive aldehydes generated from early glycation also con-
tribute to LDL modification and to the production of autoan-
tibodies in pathologic conditions (42).  the reaction of small 
aldehydes with residues on the protein surface, including 
lysine and histidine side chains, might define the neoepitopes 
of autoantibodies emanating from the nAb population. For 
example, it has been reported that antibodies induced to his-
tidine adducts of lipid oxidation-derived aldehydes also bind 
to DnA (43). Structural mimicry between these adducts and 
2-deoxyribonucleosides was suggested to explain this DnA 
binding. these antibodies have high sequence homology to 
natural anti-DnA autoantibodies and are related to the poly-
reactive nAbs. thus, the role of carbonyl residues in promot-
ing immune responses to modified self may have several di-
mensions. In an expanded context, proteins modified by two 
or three carbon aldehydes or other reactive small molecules 
often define ligands for innate immune receptors such as 
macrophage scavenger receptor and rAGe (44). Although 
covalent binding of aldehyde-modified proteins to scavenger 
receptors through Schiff base or carbinolamine adducts was 
contemplated the early investigations, such interactions be-
tween modified self and innate immune receptors, and anti-
body paratopes in particular, remain to be demonstrated.
ChEMICAL REACTIVITY, CATALYSIS AND ThE 
BASIS FOR POLYREACTIVE ANTIBODIES
Polyreactivity of nAbs is defined as the promiscuous avidity 
of multivalent IgM molecules to disparate molecules, includ-
ing intracellular proteins and nucleic acids (45). this binding 
capacity, which can also be manifested as autoreactivity to 
self, remains poorly understood in structural terms. enhanced 
avidity by the recognition of repetitive structures on self mol-
ecules or membranes provides a plausible molecular mecha-
nism for polyreactivity. Within this conceptual framework, 
the repetitive structures suggest another form of molecular 
pattern identifying the damaged cells and tissues. thus, the 
A .5 Model  А .17 Model
Fig. 5. Molecular models of the variable regions of covalent binding antibody Fv fragments. The yellow side wire model indicates the side chain Tyr 
residues participating in nucleophilic attack on the organophosphorus reagent. The Tyr at VL32 in A.5 is part of CDR1 that is oriented near the surface 
of the Fv domain, whereas Tyr at VL37 in A.17 is in FR1 at the interface between VL and VH. This model implicates a conserved active site in a deep 
cleft on A.17reVIeWS
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high density of Pc groups on oxidized phospholipids and on 
cell wall polysaccharides offers a common feature for nAb 
binding. Similarly, phosphate linkages or nucleotide sequenc-
es on DnA strands could represent the molecular pattern for 
DnA antibodies to recognize surface features of apoptotic 
cells (46, 47).
reports showing that DnA autoantibodies found in lupus 
or other autoimmune diseases have phosphodiesterase activ-
ity suggests a further case where molecular recognition in 
the Ig V domains is manifested as chemical reactivity (48). 
these antibodies utilize their binding site residues to promote 
the cleavage of DnA ligands. A remarkable feature of the 
DnA-hydrolytic autoantibodies is their dependence on met-
al ions, reminiscent of the natural DnAse enzymes (49, 50).   
However, these enzyme-like antibodies show little DnA se-
quence specificity, hydrolyzing single-stranded and double-
stranded substrates promiscuously (49, 51). Structural studies 
proposed that a catalytic site for DnA-hydrolysis could be 
encoded in a VL domain having a near-germline configura-
tion (51). In a more recent example, it was suggested that 
mutations in VH or VL that enhance DnA binding could also 
contribute to hydrolytic activities (49).  It is well established 
that anti-DnA IgG autoantibodies are significantly diversi-
fied by antigen-driven adaptive immunity (52, 53). For ex-
ample, positively charged lysine and arginine residues in the 
combining sites improve binding for anionic DnA. Yet, these 
residues could also arise from biased VH or VL germline gene 
usage (54, 55). X-ray crystallographic structure studies re-
veal that DnA-binding autoantibodies interact with DnA 
through the conventional combining site comprised of cDr 
loops (56, 57). Mutations in both VL and VH contribute resi-
dues for direct antigen contact or for conformational changes 
that indirectly improve complementarity. nevertheless, the 
ontogeny of DnA autoantibodies could also reflect the inher-
ent DnA binding activity of nAbs. DnA binding can evolve 
directly from the Pc recognition function by a single muta-
tion in the murine monoclonal nAb t15 (58). earlier reports 
also showed that DnA autoantibodies have restricted VH 
family usage (59) and can be encoded entirely by germline V 
genes without any somatic change (60-62). reactivity of the 
germline-encoded V region has also been proposed to account 
for proteolytic activity of natural autoantibodies (63).  collec-
tively, these findings strengthen the hypothesis that catalytic 
activities of Ig V regions exist as an innate immune function. 
the focus on polypeptide or oligonucleotide substrates for 
catalytic autoantibodies obscures the distinction between in-
nate and adaptive immunity, as these substrates can engage 
in extended interactions with the conventional antigen com-
bining sites. Specificity for extended features of autoantigens 
implies the work of adaptive immunity. However, broad re-
activity without regard for the substrate structures flanking 
the cleavage site suggests promiscuity of a primitive active 
site. In depth biochemical and structural investigation of the 
inherent reactive or catalytic sites of natural antibodies will 
further illuminate the biological significance of the chemical 
function.
CONCLuSIONS
covalent-binding antibodies obtained by immunization or 
reactive selection and catalytic antibodies found in autoim-
mune pathologies appear to have features in common with 
nAbs. these features include VH and VL domains in germ-
line or near-germline configurations and the recognition of 
molecules presenting uncommon chemical functionality, 
such as reactive carbonyls and phosphorus esters. Such fea-
tures may be fundamentally related in that the chemical or 
enzymatic function is presumably highly evolved and there-
fore conserved in the genome. Whereas nAbs are IgMs that 
rely on weak multivalent binding to molecular patterns on 
antigens for high avidity, chemically reactive or catalytic 
antibodies are also expressed as IgG that can bind antigens 
with high affinity. However, the latter may also react with 
diverse substrates through weak, noncovalent pre-reaction 
complexes. According to the transition state theory of catal-
ysis the strongest binding is expressed between an enzyme 
and the transition state. In the covalent complex, binding 
is dominated by the chemical bond between a residue of 
the active site and a group on the ligand. the focus of the 
weak binding by nAbs on small, minimally altered epitopes 
is consistent with the recognition of substrate functional-
ity for reactivity. thus, chemical reactivity could provide a 
mechanism to translate weak non-covalent binding to strong 
binding or to catalytic activity.  the physiological purpose of 
chemically reactive and catalytic antibodies must also be 
addressed, even as the role of nAbs in protective immunity 
and homeostasis is only beginning to emerge. Participation 
of nAbs as response elements in oxidative stress and apop-
totic cell clearance suggests a housekeeping function that 
predates the evolution of adaptive immunity. Similar con-
siderations may apply to the rationale for covalent-binding 
antibodies acting as buffers against glycation stress. the 
preservation of covalent reactivity or catalytic functions in 
adaptive responses and in autoimmunity could be attrib-
uted to biological design or to defects in immune regula-
tion. Inducibility through adaptive immunity might offer 
an appropriate mechanism to invoke beneficial responses 
to oxidative or glycoxidative stress. On the other hand, the 
role or contribution of natural catalytic autoantibodies in 
autoimmune pathology remains obscure, and their exist-
ence could simply reflect a failure in the V gene repertoire 
shift on induction of IgG autoantibodies (64, 65). Designed 
catalytic antibodies can also be educed from the adaptive 
immune response by affinity maturation that is appropriate 
for substrate reactivity or transition state binding. to what 
extent do designer catalytic antibodies co-opt the functions 
of natural autoantibody catalysts? An important clue was 
provided in an earlier report indicating a high frequency 
of antibodies with hydrolytic activity among hybridomas 
sampling an autoimmune repertoire (66). continuing stud-
ies of antibody chemical reactivity induced by immuniza-
tion or discovered in the germline repertoire should provide 
further insights into its role in immunity or pathology and 
could enable technological applications of this unconven-
tional antibody function in the future. 
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